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ABSTRACT 
Objective: To develop a new method and validate the same for the determination of Febuxostat (FBS) in human plasma by liquid chromatography–
mass spectrometry (LCMS). 
Methods: The present method utilized reversed-phase high-performance liquid chromatography with tandem mass spectroscopy. Febuxostat D9 
(FBS D9) was used as internal standard (IS). The analyte and internal standard were separated from human plasma by using solid phase extraction 
method. Zorbax Eclipse XDB, C8
Results: The parent and production transitions for FBS and internal standard were at m/z 317.1 →261.0 and 326.1→262.0 respectively. The method 
was validated for system suitability, specificity, carryover effect, linearity, precision, accuracy, matrix effect, sensitivity and stability. The linearity 
range was from 20.131 ng/ml to10015. 534 ng/ml with a correlation coefficient of 0.999. Precision results (%CV) across six quality control samples 
were within the limit. The percentage recovery of FBS and internal standard from matrix samples was found to be 76.57% and 75.03% respectively. 
, 100 mm x 4.6 mm, 3.5 µm column was used and HPLC grade acetonitrile, 5 millimolar (mM) ammonium format 
(80: 20, v/v) as mobile phase, detected by mass spectrometry operating in positive ion and multiple reaction monitoring modes. 
Conclusion: Present study describes new LC-MS method for the quantification of FBS in a pharmaceutical formulation. According to validation 
results, it was found to be a simple, sensitive, accurate and precise method and also free from any kind of interference. Therefore the proposed 
analytical method can be used for routine analysis for the estimation of FBS in its formulation. 
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Chronic hyperuricemia and gouty arthritis [1-4] have ailed humans 
for centuries. Recent advancement of research in the understanding 
of the mechanism of their progress has changed our perception of 
the disease process. In spite of these developments, the treatment 
options are limited. The FDA approval of FBS for the treatment [5-8] 
of gouty arthritis or hyperuricemia has been a significant step 
forward. Since its approval during 2009, FBS has been proved to be 
a safe and efficacious treatment, although concerns remain about its 
long-term effects and superiority over other anti-gout agents, such 
as allopurinol. 
Chemically the compound FBS is known as 2-(3-cyano-4-
isobutoxyphenyl)-4-methyl- 




Fig. 1: Chemical structure of FBS 
 
The literature survey indicates that there are certain methods 
available for the determination of FBS in bulk drug form, 
formulation, metabolites and in the spiked plasma sample. 
Spectrophotometric methods were developed [9, 10] for 
determination of FBS in bulk and formulation. Reverse phase liquid 
chromatography was developed [11-16] determination of FBS in 
bulk, formulation and plasma sample. One method was reported 
[17] for the determination of FBS by using ultra-pressure liquid 
chromatography/mass spectroscopy and also there were two 
methods [18, 19] which used liquid chromatography-mass 
spectroscopy. Our developed new method has got unique 
advantages over these existing methods which are as follows 
The proposed LC-MS method is a simple and selective for the 
determination of FBS in human plasma. The method employs only 
100 microliter of human plasma volume and achieved good 
sensitivity. Use of low plasma volume for the analysis, the sample to 
be collected per time point from an individual during the study is 
reduced significantly. This allows the inclusion of additional points. 
The analyte and the IS were extracted from plasma using one-step 
solid–phase extraction with no drying, evaporation and 
reconstitution steps. Solid–phase extraction allows higher 
recoveries and the elimination of possible interference from 
endogenous and exogenous components. Isotope-labeled compound 
used as an IS to get better precision and accuracy. The total run time 
(2.0 min) is short enough compared to existing methods and makes 
it an attractive bioanalytical procedure of FBS for bioavailability and 
also will be in pharmacokinetic studies which will be studied shortly. 
MATERIALS AND METHODS 
Instrumentation 
HPLC: Shimadzu 




Acetonitrile (HPLC grade)-JT Baker 
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Ammonium formate (AR grade)-Merck 
Formic acid (AR grade)-Merck 
HPLC grade water-Rankem 
Strata X polymeric sorbent cartridges (30 mg/1cc)-Phenomenex 
Working standards 
Drug: Febuxostat 
Batch No: VL/S-FB-004/b 
Purity: 99.59% (HPLC) 
Supplier: Vivan life sciences private limited. 
Drug: Febuxostat D9 
Batch No: VL/D-FB-206/a 
Purity: 99.96% (HPLC) 
Supplier: Vivan life sciences private limited.  
 
Mass spectrometry operating conditions 
Compound Febuxostat Febuxostat D9 
Detection Positive Positive 
M/z 317.10 (parent) 326.10 (parent)  
 261.00 (product) 262.00 (product) 
Ion spray voltage (ISV) 4000 V, 4000 V  
Temperature (TEM °C) 550 °C 550 °C 
Curtain gas (CUR) 10 psi 10 psi 
Collision gas (CAD) 10 psi 10 psi 
NEB 6 psi 6 psi 
Declustering potential (DP) 26 V 26 V 
Collision energy (CE) 26 V 26 V 
Collision cell exit potential    
(CXP) 12 V 12 V 
Focusing potential (FP) 128 V 128 V 
Entrance potential (EP) 10 V 10 V 
Dwell time 200 ms 200 ms 
 
Preparation of standard stock and plasma samples 
FBS stock solution: Weighed about 10.00 mg of FBS working 
standard and transferred to a 5 ml clean glass volumetric flask, 
dissolved in HPLC grade methanol and made up the volume with the 
same to produce a solution of 2 mg/ml. Corrected the above 
concentration of FBS solution accounting for its potency and the 
actual amount weighed.  
The stock solutions were diluted to suitable concentrations 
using a mixture of acetonitrile and HPLC grade water in the ratio 
of (60:40 v/v) for spiking into the plasma to obtain calibration 
curve (CC) standards, quality control (QC) samples and DIQC 
samples. For the preparation of calibration curve standards and 
quality control samples, two separate stock solutions were 
prepared and used. All other final dilutions (system suitability 
dilutions, aqueous mixture, etc.) were prepared in the mobile 
phase. 
Note: Stock solutions and further dilutions of FBS D9 were prepared 
under the yellow monochromatic light. 
FBS D9 Stock Solution (Internal standard): Weighed about 
2.0000 mg of FBS D9 hydrochloride, transferred to a 2 ml 
volumetric flask, dissolved in HPLC grade methanol and made up 
the volume with the same to produce a solution of 1 mg/ml. 
Corrected the above concentration of FBS D9 accounting for its 
molecular weight, potency and the actual amount weighed. The 
stock solution was diluted to a suitable concentration using 
diluent for internal standard dilution.  
Biological matrix 
Eight lots of K2-EDTA human plasma, including one lipemia and one 
hemolytic plasma, were screened for selectivity test. All eight human 
plasma lots, including hemolytic and lipemic plasma, were found 
free of any significant interference for FBS and IS. 
Selectivity and matrix test was performed before bulk spiking. After 
bulk spiking, 300 µl aliquot of each of the spiked calibration 
standards and quality control samples were pipetted out into 5 ml 
RIA vial, and stored in a deep freezer at–70 °C, except twelve 
replicates each of LQC and HQC, which were stored in a deep freezer 
at–20 °C for generation of stability data at–20 °C. 
Calibration curve standards and quality control samples 
Calibration curve standard consisting of a set of ten non-zero 
concentrations ranging from 20.131 ng/ml to 10015.534 ng/ml of 
FBS were prepared. Prepared quality control samples consisted of 
concentrations of 20.799 ng/ml (LLOQ QC), 61.174 ng/ml (LQC), 
1529.341 ng/ml (MQC1), 5097.802 ng/ml (MQC2) and 7608.659 
ng/ml (HQC) for FBS as given in table 1 and table 2. These samples 
were stored at–70 °C until use. Twelve sets of LQC and HQC were 
stored at–20 °C deep freezer to check-20 °C stability. Twenty-four 
sets of quality control samples for dilution integrity were prepared 
by spiking about 1.60 times the higher standard concentration of 
FBS (16797.041 ng/ml). From these six sets each of two times 
dilutions and four times dilutions were performed. 
 
Table 1: Calibration curve (standard)  
Final concentration- CC ( ng/ml) Label 










*CC- Calibration curve 
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Table 2: Quality control (sample) 





D1QC (ULQC) 16797.041 
*LLOQ- Lower limit of quantification, QC- Quality control, LQC- Low-quality control, MQC- Medium quality control,  HQC-High quality control, 
DIQC- Dilution integrity quality controle. ULQC- Upper limit quality control. 
 
Sample preparation 
The samples were thawed at room temperature and vortexed to 
ensure complete mixing of the contents. 200 µl of the plasma sample 
was pipetted in 5 ml polypropylene RIA vial, 20 µl of internal 
standard dilution (30598.856 ng/ml of FBS D9) was added to it and 
vortexed, except in blank plasma samples where 20 µl diluents was 
added and vortexed. Then, 600 µl of 0.1% formic acid buffer was 
added and vortex. The analyte and the IS were extracted from 
plasma using one-step solid–phase extraction with no drying, 
evaporation and reconstitution steps. SPE allows higher recoveries 
and the elimination of possible interference from endogenous and 
exogenous components. The sample mixture was loaded into the 
strata X 33 µm polymeric sorbent (30 mg/1 ml) cartridges that were 
preconditioned with 1.0 ml of HPLC grade methanol followed by 1.0 
ml Milli Q HPLC grade water (new cartridge for each sample). After 
applying the maximum pressure, the extraction cartridge was 
washed with 2 ml of Milli Q/HPLC grade water (1.0 ml of each time). 
Then the samples were eluted with 1 ml of mobile phase and 
transferred to autosampler loading vials (amber color) and loaded 
into the auto-sampler. 
Method development 
Chromatographic separation was achieved after several trials using 
various combinations of solvents like acetonitrile, methanol, buffer 
(ammonium acetate, ammonium formate, formic acid, acetic acid at 
different concentrations) with varying proportions of each 
component on different columns like C18 and C8 of different brands 
like Grace, Chromolith, Hypersil, Hypurity advance, Kromasil, 
Zorbax, Ace and Intertsil. Use of 5 mM ammonium formate buffer 
helped in achieving good response for the detection in the positive 
ionization mode.  
Validation parameters 
Chromatography: Chromatographic conditions were optimized to 
achieve good sensitivity and peak shapes for the compounds, as well 
as a runtime which could be as short as it is possible. The liquid 
chromatographic conditions were optimized after a number of trials. 
A mobile phase consisting of acetonitrile and ammonium formtate 5 
mM buffer (80:20, v/v) was found the most suitable. Zorbax eclipse 
XDB, C8, 100 x 4.6 mm, 3.5 µm (make: Agilent technology) column 
was the most useful one for developing the method.  
System suitability 
System suitability study was performed by applying six consecutive 
applications of FBS and FBS D9 LLOQ concentration and thereby 
observing the results in terms of retention time and area response 
and calculating %CV. 
Selectivity 
Selectivity test of the developed new method was conducted by 
injecting blank human plasma, spiked six samples at concentrations 
of (ULOQ) for FBS and the internal standard in plasma, compared 
the responses FBS and internal standard in the blank with a mean 
response of applied (ULOQ). The peak area of FBS at the respective 
retention time in blank should not be more than 20% of the mean 
peak area of (ULOQ) of FBS. Similarly, the peak area of FBS D9 at the 
respective retention time in blank should not be more than 5% of 
the mean peak area of (ULOQ) of FBS D9. Observations were there, 
whether any interfering compounds appeared in the chromatogram. 
Sensitivity 
The lower limit of reliable quantification for FBS in human plasma 
was set in the concentration of the LLOQ 20.131 ng/ml. The 
precision and accuracy for the analyte should be calculated and 
results in terms of accuracy and precision should be verified 
whether they are within the limit.  
Matrix effect 
To predict the variability of matrix effects in samples from 
individual subjects, matrix effect was quantified by determining the 
matrix factor, which was calculated as follows:  
Matrix Factor = Peak response ratio in the presence of extracting 
matrix (post extracted)/Peak response ratio in aqueous standards.  
Six lots of blank biological matrices were extracted each in 
triplicates and post spiked with the aqueous standard at the low, 
high QC level, and compared with aqueous standards of the same 
concentration. The overall precision of the matrix factor is expressed 
as a coefficient of variation (CV %) and %CV should be<15%. 
Recovery 
The extraction recovery of FBS and FBS D9 from human plasma was 
determined by analyzing quality control samples. Recovery at three 
concentrations (LQC, MQC2 and HQC) was determined by comparing 
peak areas obtained from the plasma sample and the standard 
solution spiked with the blank plasma residue. 
Linearity 
A regression equation with a weighting factor of 1/(concentration 
ratio) 2 of FBS to FBS D9 concentration was judged to get the best fit 
for the concentration--detector response relationship for FBS in 
plasma. The correlation coefficient (r2
Precision and accuracy 
) value should be greater than 
0.99 in the designed concentration range for FBS. 
The accuracy of the developed method is defined as the absolute 
value of the ratio of the calculated mean values of the LLOQ, low, 
middle and high-quality control samples to their respective nominal 
values, expressed in percentage. The precision of the developed 
method was measured by the percent coefficient of variation over 
the concentrations of LLOQ QC, LQC, MQC and HQC samples during 
the course of validation 
Stability studies 
Stability studies were performed by taking the sample passed 
through different physicochemical conditions like bench top, freeze-
thaw, wet extract, dry extract, autosampler, dilution integrity, long 
term stability, etc.  
RESULTS AND DISCUSSION 
Method development 
Optimization of liquid chromatography and mass spectrometry 
conditions 
A detailed comparative study of the various published methods with 
the newly developed method is discussed in table 3. During method 
development while conducting trials, it was observed that increase 
in the proportion of buffer in mobile phase resulted in increased 
retention time, reduction in flow rate below 1 ml/minute also 
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increased the retention time, similarly reduction of column 
temperature below 40 °C also contributes in prolongation of retention 
time. However, there was no substantial amount of variation in the 
number of theoretical plates or tailing factor. With the optimized 
method condition, we could able to limit the moderate run time that is 
2 min, which is short enough compared to the existing method [18, 19] 
which used liquid chromatography-mass spectroscopy.  
Moreover, if we look at the peak obtained in the case of Febuxostat 
D7 in the method developed by Babu Rao Chandu, Kanchanamala 
Kanala, Nagiat T Hwisa, Prakash Katakam, Mukkanti Khagga [19] it 
seems there were certain impurities along with the compound as the 
main peak was closely accompanied with additional peak. It may be 
an interference effect also. However, in our proposed method no 
such issues are associated. 
  
Table 3: Comparative table of FEB 
Method Solvent system Con. range Detection Reference 
UV spectroscopy Methanol 0.2-15 µgm/ml 315 nm [9] 
UV spectroscopy Zero order Methanol 
 
2-30 µgm/ml 314 nm [10] 
First order 1-30 µgm/ml 293-336 nm 
RP-HPLC Sodium acetate, ACN 0.1-200 µgm/ml 254 nm [11] 
RP-HPLC Methanol, OPA 45.42-2559.64 ngm/ml 310 nm [12] 
RP-HPLC Ammonium acetate, ACN 50-400 µgm/ml 275 nm [13] 
RP-HPLC Methanol, ACN 40-100 µgm/ml 218 nm [14] 
RP-HPLC Pot. di. H. PO4, ACN 5-60 µgm/ml 320 nm [15] 
RP-HPLC Methanol, Sodium acetate 250-8000 ng/ml 315 nm [16] 
UPLC-MS Formic acid, ACN 2-10000 µgm/ml MRM-MD [17] 
LC-MS Formic acid, CAN, water 10-20000 ng/ml MRM-MD [18] 
LC-MS Ammonium formate, ACN 1-8000 ng/ml MRM-MD [19] 
*CAN-Acetonitrile, OPA-Ortho phosphoric acid, Pot. di. H. PO4-Potassium dihydrogen phosphate, MRM-Multi reaction monitoring mode, MD-Mass detector. 
 
In the present method, separation was achieved by using mobile 
phase as Acetonitrile and 5 mM ammonium formate (80:20, v/v) 
in isocratic elution technique at a flow rate of 1.00 ml/min. fig. 2 
represents the mass spectra of FEBU and FEBU D9. Fig. 3 
represents chromatogram of the blank plasma and blank plasma 
with internal standards.  
Method Validation  
System suitability 
Consecutive six injections were applied for FBS and IS LLOQ 
concentration in the chromatographic system. The mean retention 
time was found to be 0.9733 min and 0.9616 min respectively. If it is 
compared with any other existing method [18, 19] it is easy to 
understand the rapid nature of the present method. Mean area, 
standard deviation, and %CV were found to, 18528.0 and 
2508497.3, 1805.26 and 223043.3, 9.74 and 8.89 for FBS and IS 
respectively which are well within the acceptable limit. 
Selectivity and specificity 
The selectivity and specificity of the present analytical method were 
established by examining any interfering compounds which elute 
along with FBS. The response of both analyte and IS in blanks was 
compared with the mean response of injected LLOQ. 
 
Fig. 2: Q1/Q3 mass spectrum of FBS along with the IS 
 
Fig. 3: Chromatogram of blank plasma sample of FBS and FBS D9 
 
There were no interfering peaks formed at FBS retention time and IS 
retention time in the plasma blanks. Fig. 4 shows chromatograms of 
blank human plasma samples. The results were shown in table 4 and 
table 5. The analytical study of FBS and FBS D9 using the multiple 
reaction monitoring functions was highly selective and no 
interfering compounds were observed. 
Recovery 
As the sample and internal standard FBS D9 were extracted from 
human plasma, and the test for recovery was determined by 
analyzing quality control samples (LQC, MQC2 and HQC) by means 
of comparison of peak areas obtained from the plasma sample and 
the standard solution spiked with the blank plasma residue, the 
average percentage recoveries were found to be 76.56% and 
75.03% respectively. This yield is up to the mark and comparable 
with any other mass spectrophotometric method. Detailed results 
are narrated in table 6 and table 7. 
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Table 4: Result of system suitability 
S. No. tR Peak response (area) LLOQ  in Minutes 
Analyte Internal standard Analyte Internal standard 
1 0.97 0.96 15844 2213163 
2 0.97 0.96 17086 2300690 
3 0.97 0.96 20729 2748657 
4 0.97 0.96 18409 2461078 
5 0.98 0.97 19729 2735237 
6 0.98 0.96 19371 2592159 
Mean (±) 0.973 0.961 18528.0 2508497.3 
SD 0.00516 0.00408 1805.26 223043.34 
CV% 0.530 0.424 9.74 8.89 
*tR-Retention time, LLOQ-Lower limit of quantification 
 
Table 5: Specificity of FBS and internal standard 
Sample Id FBS Peak area IS peak area % interference at tR % interference at of FBS  tR of IS 
ULOQ FBS 1 6125002 0 NA 0 
ULOQ FBS 2 5948204 0 NA 0 
ULOQ FBS 3 5658120 0 NA 0 
ULOQ FBS 4 5450620 0 NA 0 
ULOQ FBS 5 5408965 0 NA 0 
ULOQ FBS 6 6844515 0 NA 0 
The mean response of FBS in presence of IS 5905904    
Mean response of FBS D9 in presence of FBS  0  0 
Blank+IS (FBS D9) 1 0 1996826 0 NA 
Blank+IS (FBS D9) 2 0 2123014 0 NA 
Blank+IS (FBS D9) 3 0 1858814 0 NA 
 Blank+IS (FBS D9) 4 0 2087960 0 NA 
 Blank+IS (FBS D9) 5 0 2133141 0 NA 
Blank+IS (FBS D9) 6 0 1999478 0 NA 
Mean response of FBS D9 in presence of FBS  2033210   
Mean response of FBS   0  
* ULOQ-Upper limit of quantification, FBS-Febuxostat, IS-Internal standard, tR-
 
Retention time, NA-Not applicable. 
Table 6: Recovery of FBS from matrix 
Standard Identifying 
code 
Unextracted standard peak 
area 






































































































*LQC-Low quality control, AQS-Aqueous, EXT-Extracted, SD-Standard deviation, CV-Co-efficient of variance, MQC-Medium quality control, HQC-High 
Quality control.  
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Table 7: Recovery of internal standard from matrix 
Standard  Identifying code Unextracted peak area Identifying code Extracted peak area %recovery 









































































Mean (±)  2440933  1831376.3  
SD  154156.27  69079  
%CV  6.32  3.77  
*FBS-Febuxostat, LQC-Low quality control, AQS-Aqueous, SD-Standard deviation, CV-Co-efficient of variance, MQC-Medium quality control, HQC-
High Quality control.  
 
Linearity, accuracy, and precision 
Linearity, accuracy, and precision: The calibration curve was 
constructed using 8 calibration standards ranging from 
20.131ng/ml to 10015.534ng/ml. a straight line fit was made 
through the data points. The correlation coefficient was found to 
be ≥0.999. The lower limit of quantification (LLOQ) was found to 
be 20.799ng/ml. Accuracy was calculated in terms of percentage 
recovery and precision in terms of percentage coefficient 
variation. For the concentration of LLOQ the accuracy result and 
precision value were found to be 100.10% and CV% 5.69 
respectively. The test result for inter-batch accuracy was 97.91%; 
precision for LLOQ, LQC, MQC and HQC was 4.96, 3.77, 3.47 and 
2.18 respectively. The test result for inter-batch accuracy was 
99.77% (first batch), 97.24% (second batch); precision for LLOQ, 
LQC, MQC and HQC for the first batch was 3.04, 3.62, 4.44 and 
0.64; for second batch 4.49, 1.13, 2.90 and 0.69 respectively. The 
test result for intraday accuracy was 98.51%; precision for LLOQ, 
LQC, MQC1, MQC2 and HQC was 3.85, 2.72, 4.36, 4.46 and 1.49 
respectively. All the results of linearity, accuracy, and precision 
were within the limit. Fig. 4 represents the calibration curve, fig. 5 
to fig. 9 represent the chromatograms of FBS and FBS D9 for the 
concentrations of LLOQ, LQC, MQC1 and HQC. Table 8 to table11 
contains the results of accuracy and precision. 
  
 
Fig. 4: Calibration curve for regression analysis of FBS 
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Fig. 5: Chromatogram of LLOQ QC sample of FBS and FBS D9 
 
 
Fig. 6: Chromatogram of LQC sample of FBS and FBS D9 
 
Table 8: Precision and accuracy for LLOQ (sensitivity) 
FBS 
 Identifying code  Nominal (ng/ml) % Accuracy 
LLOQ-1 19.892 98.81 
LLOQ-2 20.982 104.23 
LLOQ-3 18.861 93.69 
LLOQ-4 19.183 95.29 
LLOQ-5 21.931 108.98 
LLOQ-6 20.054 99.62 
Mean 20.1518  
SD 1.14587  
CV% 5.69  
% nominal 100.10  
*Number of replicates = 6, FBS-Febuxostat, LLOQ-Lower limit of quantification, SD-Standard deviation, CV-Co-efficient of variance. 
Pal et al.  




Fig. 7: Chromatogram of MQC1 sample of FBS and FBS D9 
 
 
Fig. 8: Chromatogram of MQC2 sample of FBS and FBS D9 
 
Table 9: Inter batch precision and accuracy 
Batch LLOQ (ng/ml)  LQC (ng/ml)  MQC1 (ng/ml)  MQC2 (ng/ml)  HQC (ng/ml)  
QC 20.779 %Accuracy 61.174 %Accuracy 1529.341 %Accuracy 5097.802 %Accuracy 7608.659 %Accuracy 
Mean 20.3139 97.6 58.1238 95.01 1529.5868 99.49 4887.0549 95.87 7449.3205 97.91 
SD 1.00710  2.18880  3.79  169.56247  162.41094  
CV% 4.96  3.77  99.49  3.47  2.18  
*Number of replicates = 30, LQC-Low quality control, MQC-Medium quality control, HQC-High Quality, SD-Standard deviation, CV-Co-efficient of 
variance control. 
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Fig. 9: Chromatogram of HQC sample of FBS and FBS D9 
 
Table 10: Intraday precision and accuracy 
 LLOQ (ng/ml)  LQC (ng/ml)  MQC1 (ng/ml)  MQC2 (ng/ml)  HQC (ng/ml)  
QC 20.799 %Accuracy 61.174 %Accuracy 1529.341 %Accuracy 5097.802 %Accuracy 7608.659 %Accuracy 
Mean 20.4502 98.32 58.2138 95.16 1493.5383 97.66 4847.3108 95.09 7495.0603 98.51 
SD 0.78632  1.58526  65.06109  215.9665  111.369  
CV% 3.85  2.72  4.36  4.46  1.49  
*Number of replicates = 12, QC-Quality control, LLOQ-Lower limit of quantification, LQC-Low quality control, MQC-Medium quality control, HQC-
High Quality, SD-Standard deviation, CV-Co-efficient of variance control. 
 
Table 11: Intra batch precision and accuracy 
Batch LLOQ (ng/ml)  LQC (ng/ml)  MQC1 (ng/ml)  MQC2 (ng/ml)  HQC (ng/ml)  
QC 20.799 %Accuracy 61.174 %Accuracy 1529.34 %Accuracy 5097.802 %Accuracy  %Accuracy 
1st batch 
Mean 20.6940 99.50 58.7045 95.96 1457.2373 95.29 4806.0205 94.28 7591.3512 99.77 
SD 0.62943  2.12693  64.67799  262.02031  48.95283  
CV% 3.04  3.62  4.44  5.45  0.64  
N 6  6  6  6  6  
2nd batch 
Mean 20.2063 97.15 57.7230 94.36 1529.839 100.03 4888.60 95.90 7398.769 97.24 
SD 0.90631  0.65334  44.34646  172.81499  51.36160  
CV% 4.49  1.13  2.90  3.54  0.69  
*N-Number of replicates = 6, QC-Quality control, LLOQ-Lower limit of quantification, LQC-Low quality control, MQC-Medium quality control, HQC-
High Quality control, SD-Standard deviation, CV-Co-efficient of variance. 
 
Carry over effect 
The sequence of injections consisting two blank samples and two 
samples of ULOQ concentration were analyzed alternately to find 
out if there is any carry over affect on the blank sample. It was found 
that there was no carryover effect observed in the present method. 
Stability results 
As stability studies were performed by taking FBS passed through 
different physicochemical conditions like bench top, freeze-thaw, 
wet extract, dry extract, autosampler, dilution integrity, long-term 
stability, the mean response, percentage recovery and percentage 
coefficient variation were found within the limit. Table 12 
represents the results of stability studies in details. 
Dilution integrity 
Dilution integrity was performed by taking two times and four times 
dilution of ULOQ concentration (16797.041 ng/ml). The percentage 
accuracy and %CV were found to be within the acceptance criteria 
(table 13). 
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Table 12: Stability data of QC samples in human plasma 




Bench top 15 h 59.1428 96.68 5.90 
Freeze-thaw 59.7635 97.69 3.64 
Wet extract 62.6802 102.46 5.75 
Autosampler 60.0737 98.20 4.16 
Freshly spiked QC 58.4463 95.56 1.77 




Bench top 15 h 7608.659 100.95 1.20 
Freeze-thaw 7737.6602 101.70 1.61 
Wet extract 7803.0808 102.56 1.19 
Autosampler 7714.5567 101.39 1.22 
Freshly spiked QC 7756.0290 101.96 0.72 
60 d 7656.8233 100.63 0.80 
 *Number of replicates, QC-Quality control, LQC-Low quality control, HQC-High quality control, CV-Co-efficient of variance. 
 
Table 13: Data acquired on dilution integrity 
Nominal concentration (NC) ng/ml 
DIQC Two times dilution Four times dilution 
NC = 16797.041 % Accuracy NC = 16797.041 % Accuracy 
Mean 16355.7257 97.37 16542.7382 98.49 
SD 444.99782  436.31186  
CV% 2.72  2.64  
*DIQC-Dilution integrity quality control, NC-Nominal concentration, SD-Standard deviation, CV-Co-efficient of variation. 
 
CONCLUSION 
The new developed method is a rapid, simple, specific and accurate 
liquid chromatography mass spectrophotometry for the 
determination of FBS as the results of all the validation parameters 
were found within the limit. The sophisticated solid phase extraction 
technique has yielded in high precision values. As per Cmax
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